PreludeDx
PrivateLast Round
VC Round
Mar 22, 2022
Total Funding Raised
$3.51M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
PreludeDx is a biotechnology company that develops and provides precision diagnostic tests for early-stage breast cancer.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PreludeDx Comparables
Compare PreludeDx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Agendia | 88% | |
| Silbiotech, Inc. | 78% | |
| Hologic, Inc. | 78% |
PreludeDx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 22, 2022 | ||||
| Strategic | Jul 19, 2021 | ||||
| Grant | Jan 1, 2014 | ||||
| Series A | Jul 27, 2011 |
Key People
Founding team and executive leadership
PreludeDx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Fjord Ventures | VC Round, Series A |
| Evidity Health Capital | VC Round |
| BlueStone Venture Partners | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 40% MoM.
- Apr 29, 2026
Received designation for AidaBreast test for early-stage invasive breast cancer.
Recent news
Latest coverage and updates
- partners_withJul 9, 2026
PreludeDx partnered with Learn Look Locate, LLC on Jul 9th '26.
- launchesJul 9, 2026
PreludeDx launched patient-centered educational resource on Jul 9th '26.
PreludeDx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about PreludeDx's valuation, stock price, and market status.
Is PreludeDx a public or private company?
PreludeDx is a private company.
What is the current stock price of PreludeDx?
PreludeDx is a private company with no public stock price. No recent secondary market data is available.
How much is PreludeDx worth (valuation)?
Valuation information for PreludeDx is not publicly available.
Can I buy PreludeDx stock?
PreludeDx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was PreludeDx's last funding round?
PreludeDx's most recent funding round was VC Round on March 22, 2022.
Who are the main investors in PreludeDx?
Key investors in PreludeDx include National Cancer Institute, Fjord Ventures, Evidity Health Capital.
Will PreludeDx IPO soon?
No public IPO plans have been announced for PreludeDx.
How can I track PreludeDx secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PreludeDx's secondary market activity and sign up for updates.